Scintix (radiotherapy system)

2023: Product Announcement

On August 23, 2023, RefleXion Medical announced the launch of the Scintix radiation therapy system with biological control. The complex is intended for the treatment of malignancies in both early and late stages.

It is noted that Scintix therapy is an advanced radiopharmaceutical method of cancer treatment, based on the individual biological assessment of each tumor to optimize the treatment program. In particular, based on the obtained data, the system calculates the required radiation dose. Moreover, the indicator can vary in real time during the procedure.

Biologically controlled Scintix radiation therapy can be used for patients with lung and bone tumors. Such malignancies formations may result from primary cancer or metastatic lesions. U.S. Food and Drug Administration (FDA) assigned the status of a breakthrough technology for the treatment of lung malignancies to a new type of therapy.

Scintix tumor therapy monitors cancer cell emissions resulting from the injection of a radioactive pharmaceutical into a patient. This allows you to target tumor structures. The platform is suitable for treating patients with solid tumors at any stage. The new type of therapy, among others, will be used by cancer centers in California, Pennsylvania, Texas, New Jersey, Connecticut and Oregon.

Scintix is a watershed moment for both physicians and patients, as the technology is capable of addressing the challenges of treating metastatic diseases, said Todd Powell, president and CEO of RefleXion Medical.[1]

Notes